Showing results (71-80 of 163) with videos related to
Sort By:
Pageof 17
Cancer Medicine|May 24, 2022
The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in JapanTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Oncology|August 20, 2024
Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective AnalysisTakeshi Hatanaka, Naoto Saito, Satoru Kakizaki, et al.Journal of Gastroenterology and Hepatology|November 14, 2025
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular CarcinomaTakanori Ito, Shigeo Shimose, Issei Saeki, et al.Liver International : Official Journal of the International Association for the Study of the Liver|November 28, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class BRyu Sasaki, Shigeo Shimose, Issei Saeki, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 21, 2026
Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRITomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, et al.Journal of Gastroenterology|April 12, 2026
Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world studyHisashi Kosaka, Rie Sugimoto, Masahiko Kinoshita, et al.Hepatology International|June 12, 2026
Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinomaKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.Oncology Letters|July 9, 2024
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practiceShigeo Shimose, Issei Saeki, Tetsu Tomonari, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 11, 2025
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early-Stage Viral DiseaseKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinomaTakanori Ito, Shigeo Shimose, Joji Tani, et al.Pageof 17